News & Events

Category: News

Advancing Management of Rheumatoid Arthritis — A conversation with researchers about the impact of their research

Vivli Board Member Dr. Stewart recently connected with researchers Prof. José António P. Da Silva and Dr. Ricardo J.O. Ferreira from the University of Coimbra to discuss the value of clinical trials, data sharing and specifically what we’ve learned about advances in rheumatology.

Dr. Ferreira and Prof. Da Silva used the Vivli platform to request data and recently published, “Revisiting the use of remission criteria for rheumatoid arthritis by excluding patient global assessment: an individual meta-analysis of 5792 patients,” in the Annals of the Rheumatic Diseases.

You can watch the entire conversation here or below:

Upcoming Vivli Webinar: Sharing Academic Clinical Research Data

Sharing Academic Clinical Research Data: Top Academic Administrators discuss why and how institutions can provide support

This webinar provides an introduction to why data from academic clinical research should be shared and is aimed at academic trial teams and staff. The panelists will take part in a free-flowing conversation and Q&A to share their experiences and perspectives in setting up an institutional framework to support sharing academic clinical research trial data. Join us for a conversation discussing current initiatives, challenges to data sharing, and how they are being overcome at academic institutions.

The webinar will be held on June 18th at 9:00 am PT / 12:00 pm ET / 5:00 pm GMT.

Recording

Key topics to be covered:

  • The importance of sharing clinical research data
  • Creating an institutional framework for sharing data
  • Overcoming pain points to data sharing

Panelists include: 

Moderator: Ida Sim, Co-Founder, Vivli & Professor of Medicine, UCSF
Dan Ford, Vice Dean for Clinical Investigation, Johns Hopkins University
Susanna Naggie, Vice Dean for Clinical Research, Duke
Kim Serpico, Associate Director for IRB Operations, Harvard
Ara Tahmassian, Chief Research Compliance Officer, Harvard

 

Vivli awarded contract to improve access to Antimicrobial Resistance Surveillance data

Vivli is pleased to announce that following on from the Wellcome Trust-Open Data Institute (ODI) AMR pilot, Wellcome has awarded a contract to Vivli which aims to improve the access and research use of antimicrobial resistance (AMR) surveillance data.

The Wellcome-ODI pilot project focused on gathering and openly publishing data on industry-sponsored human antimicrobial surveillance programs. Vivli will develop a plan to foster increased research using the surveillance data in collaboration with a Steering Committee of industry data contributors. The Steering Committee, as well as a Scientific Advisory Board, will help steward the project forward.

“Our hope is that the research project will further advance understanding in the medical community, global organizations such as the United Nations and the World Health Organisation, and wider society,” said Rebecca LI, Vivli Executive Director and lead for the project. “We would like to thank the Open Data Institute and all companies and stakeholders who took part in this initiative.”

Insight Enterprises, Vivli’s long-time partner, will undertake the technical development of the platform linked to this grant.

For any enquiries or questions about the new AMR register please fill out the contact form below:


    website is protected by reCAPTCHA v3

    Bill & Melinda Gates Foundation joins Vivli as a member

    The Foundation will support its grantees to cover the costs related to sharing clinical trial data.

    The Bill & Melinda Gates Foundation has joined Vivli as a member. The Foundation will support grantees to use the Vivli platform as an approved repository for their clinical trial data.

    “By depositing and sharing data via a stable and recognized platform, this ensures the grantee’s data will be able to be reused in a sustainable manner to further enhance scientific insights” said Rebecca Li, Vivli’s Executive Director

    “We believe that the tools and discoveries capable of helping us tackle the world’s most pressing challenges – from age-old diseases like malaria to newer threats like COVID-19 – can only be realized through innovative thinking and global collaboration. Access to data is critical for both of these things. This is why we are committed to increasing the impact of the research we fund so that it is findable, accessible, interoperable, and reusable through platforms like the one developed by Vivli,” Steven Kern, Deputy Director, Quantitative Sciences, The Bill & Melinda Gates Foundation.

    “We’re delighted to have the  Bill & Melinda Gates Foundation join as a member of Vivli and make this valuable data available. We welcome researchers interested in these important trials to visit the Vivli platform to access these datasets and potentially uncover new scientific discoveries,” said Li. “The Vivli platform is a secure and user-friendly platform to archive and share data from clinical trials, and we look forward to welcoming more funders to support their grantees to share their clinical research in the Vivli platform.”

    Vivli Executive Director Dr. Rebecca Li to speak at Front Line Genomics Webinar

    Front Line Genomics will be featuring Vivli’s Executive Director, Dr. Rebecca Li, in their webinar series COVID & Genomics ONLINE, on Wednesday May 5th in the webinar, “COVID-19 Data Sharing.”

    Front Line Genomics is a genomics-focused media company, with a social mission to deliver the benefits of genomics to patients faster.

    In this webinar, they will discuss how researchers across the globe mobilized to share COVID genomic data, and whether the coronavirus pandemic has changed our perceptions of data sharing moving forward. Dr. Li will speak directly on the topic, “Data sharing in a time of pandemic.”

    Register for Dr. Li’s presentation, which takes place Wednesday, May 5th at 10:00am EDT and learn more here.

    Alnylam signs up as a member of Vivli

    Anonymized patient-level data from Alnylam available on the Vivli platform

    “We are thrilled to welcome Alnylam as a member of Vivli,” said Rebecca Li, Vivli Executive Director. “Alnylam is showing its leadership by sharing its data using the Vivli platform.

    Alnylam is leading the translation of RNA interference (RNAi) into a new class of innovative medicines with the potential to transform the lives of patients who have limited or inadequate treatment options in a number of therapeutic areas.

    “We are delighted to be able to share our clinical trial data with researchers through Vivli,” said Jenny Petersen, Director, Clinical Trial Disclosure and Transparency at Alnylam Pharmaceuticals. “We are proud we are able to take this step forward in our data sharing program as part of our ongoing data transparency commitments.”

    For more information about the conditions for accessing Alnylam data, please visit their member page. For additional information about Membership in Vivli, learn more here.

    Otsuka joins as Vivli’s newest member

    “Vivli is delighted to have Otsuka join as our newest member,” said Rebecca Li, Vivli Executive Director. “They are making an important contribution in sharing their trial data with researchers to advance science.”

    Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: “Otsuka–people creating new products for better health worldwide.” Otsuka Pharmaceutical Co., Ltd. and its subsidiaries, such as Otsuka Pharmaceutical Development & Commercialization, Inc., research, develop, manufacture, and market innovative products, with a focus on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health.

    In pharmaceuticals, Otsuka is a leader in the challenging areas of mental, renal and cardiovascular health and has additional research programs in oncology and on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate how Otsuka is a “big venture” company at heart, applying a youthful spirit of creativity in everything it does.

    “We are excited to join Vivli’s global data sharing platform to help advance clinical development and innovation,” said Christoph Koenen, MD, executive vice president and chief medical officer, from Otsuka Pharmaceutical Development & Commercialization, Inc. “Patients are at the center of everything we do at Otsuka and data sharing is increasing in importance as we develop novel treatments for people living with complex diseases.”

    For more information about the data Otsuka will share on Vivli, please visit their member page. For additional information about Vivli membership, learn more here.

    Vivli Executive Director Dr. Rebecca Li to speak at HRB-Trials Methodology Research Network Webinar

    Health Research Board Trials Methodology Research Network (HRB TMRN) will be featuring Vivli’s Executive Director, Dr. Rebecca Li, on their upcoming webinar, “Implementation of Data Sharing platforms and How Researchers are Utilizing these Platforms to Further their Research.”

    The HRB-Trials Methodology Research Network (HRB-TMRN) is a collaborative initiative between a number of Irish and international higher education institutes and methodology centers.

    Its’ mission is to strengthen the methodology and reporting of trials in health and social care in Ireland so that they become more relevant, accessible and influential for patients and other service users, practitioners, policy makers and the public. This is achieved through a program of work relating to the methodology of trials and focused on (i) support (ii) training and education (iii) research and innovation and (iv) public engagement.

    Register for Dr. Li’s presentation, which takes place Monday, April 12th 9:00-10:00 EDT (2:00-3:00pm GMT), and learn more here.

    Wellcome Trust awards Vivli grant to improve access to Covid-19 clinical trial data

    Vivli has received a grant from the Wellcome Trust, which aims to improve the access and re-use of COVID-related clinical trials data. This will include data from trials funded by the Coronavirus Therapeutics Accelerator (CTA), an initiative launched by the Bill & Melinda Gates Foundation, Wellcome and Mastercard to speed up the response to the Covid-19 pandemic by identifying, assessing, developing, and scaling up Covid-19 treatments. Vivli has received these funds as part of the consortium’s efforts to encourage and enhance the sharing of COVID-19 data.

    “Vivli is delighted that we have received this timely grant from the Wellcome Trust as it will serve to enhance our ongoing efforts in COVID to accelerate access,” said Rebecca Li, Vivli Executive Director. “Coronavirus is currently the most searched term on our Vivli platform.”

    Additionally, the grant will help Vivli improve its existing infrastructure to make studies that are available on Vivli easier to find and surface more data usage metrics. In addition, the grant provides funding for Vivli to work with the Infectious Disease Data Observatory (IDDO) to make COVID studies in its platform also available for searching and requesting on Vivli.

    The grant will provide funding over a three-year period. Insight Enterprises, Vivli’s long-time partner, will undertake the technical enhancements on the Vivli platform that are linked to this grant.

    About Vivli

    Vivli is a non-profit organization working to advance human health through the insights and discoveries gained by sharing and analyzing data. It is home to an independent global data-sharing and analytics platform which serves all elements of the international research community. The platform includes a data repository, in-depth search engine and cloud-based analytics, and harmonizes governance, policy and processes to make sharing data easier. Vivli acts as a neutral broker between data contributor and data user and the wider data sharing community. For more information, visit www.vivli.org and follow us on Twitter @VivliCenter.

    About IDDO

    Launched in 2016, the Infectious Diseases Data Observatory (IDDO) is a scientifically independent, multi-disciplinary coalition of the global infectious disease community. It provides an environment for equitable data sharing as well as the methods and infrastructure to harmonise and translate data into evidence that improves outcomes for patients worldwide. IDDO builds on and incorporates the pioneering work of the WorldWide Antimalarial Resistance Network (WWARN), a collaborative data-sharing framework begun in 2009 that proved it was possible to produce policy-changing scientific evidence from historical data.

    Vivli releases latest version of its platform

    We are delighted to announce the latest release of the Vivli platform, version 1.7, which has several new features including an updated suite of tools and software available in the research environment, greater flexibility in the data upload process and improved reporting.

    We have updated the complete suite of tools and software available in Vivli’s research environment to reflect these changes. Any researcher environments provisioned after March 6, 2021 date will have this software included as standard and existing research environments can have these updated software and packages included upon request.

    Reach out to support@vivli.org for more information.